156 related articles for article (PubMed ID: 36428710)
21. A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy.
Lam ST; Huang H; Fang X; Wang Z; Hong H; Ren Q; Tian Y; Lin S; Lin T
Cancer Manag Res; 2020; 12():1981-1990. PubMed ID: 32231439
[TBL] [Abstract][Full Text] [Related]
22. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
Lim SH; Hong JY; Lim ST; Hong H; Arnoud J; Zhao W; Yoon DH; Tang T; Cho J; Park S; Ko YH; Kim SJ; Suh C; Lin T; Kim WS
Ann Oncol; 2017 Sep; 28(9):2199-2205. PubMed ID: 28911074
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
[TBL] [Abstract][Full Text] [Related]
25. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
[TBL] [Abstract][Full Text] [Related]
26. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
[TBL] [Abstract][Full Text] [Related]
27. Expression of programmed death-1 in cutaneous extranodal natural killer/T-cell lymphoma and its effect on clinical findings and biological behaviour.
Kim YJ; Won CH; Chang SE; Lee MW; Choi JH; Lee WJ
J Eur Acad Dermatol Venereol; 2017 May; 31(5):821-827. PubMed ID: 28190256
[TBL] [Abstract][Full Text] [Related]
28. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
Haverkos BM; Pan Z; Gru AA; Freud AG; Rabinovitch R; Xu-Welliver M; Otto B; Barrionuevo C; Baiocchi RA; Rochford R; Porcu P
Curr Hematol Malig Rep; 2016 Dec; 11(6):514-527. PubMed ID: 27778143
[TBL] [Abstract][Full Text] [Related]
29. Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome.
Li PF; Mao YZ; Bai B; Gao Y; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
Ann Hematol; 2018 Dec; 97(12):2381-2389. PubMed ID: 30116872
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells.
He C; Liu B; Wang HY; Wu L; Zhao G; Huang C; Liu Y; Shan B; Liu L
BMC Cancer; 2022 Oct; 22(1):1100. PubMed ID: 36303126
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor.
Wang L; Liao DZ; Zhang J; Xia ZJ; Peng XW; Lu Y
Med Oncol; 2013 Dec; 30(4):723. PubMed ID: 24037346
[TBL] [Abstract][Full Text] [Related]
32. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
[TBL] [Abstract][Full Text] [Related]
33. High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL).
Rong Q; Gao Y; Cai Q; Wang X; Bai B; Ping L; He H; Rao H; Zhang Y; Li Z; Cai Q; Jiang W; Huang H
Expert Rev Anticancer Ther; 2021 Jan; 21(1):121-127. PubMed ID: 33397158
[No Abstract] [Full Text] [Related]
34. Atezolizumab in combination with intrathecal chemotherapy and radiation for treatment of isolated cerebral nervous system relapse in a patient with extranodal NK/T cell lymphoma: a case report.
Lipsitt AE; Hung JY; Langevin AM
J Med Case Rep; 2021 Mar; 15(1):102. PubMed ID: 33663601
[TBL] [Abstract][Full Text] [Related]
35. First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type.
Wu W; Chen X; Li N; Luo Q; Zou L
Ann Hematol; 2022 Jul; 101(7):1557-1565. PubMed ID: 35585247
[TBL] [Abstract][Full Text] [Related]
36. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
37. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.
Fox CP; Civallero M; Ko YH; Manni M; Skrypets T; Pileri S; Kim SJ; Cabrera ME; Shustov AR; Chiattone CS; Horwitz SM; Dlouhy I; Spina M; Hitz F; Montoto S; Nagler A; Martinez V; De Souza CA; Fernandez-Alvarez R; Ballova V; Gabús R; Inghirami G; Federico M; Kim WS
Lancet Haematol; 2020 Apr; 7(4):e284-e294. PubMed ID: 32105608
[TBL] [Abstract][Full Text] [Related]
38. Extranodal natural killer/T-Cell lymphoma: A population-based comparison of sinonasal and extranasal disease.
Vazquez A; Khan MN; Blake DM; Sanghvi S; Baredes S; Eloy JA
Laryngoscope; 2014 Apr; 124(4):888-95. PubMed ID: 24114591
[TBL] [Abstract][Full Text] [Related]
39. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.
Kawamoto K; Miyoshi H; Suzuki T; Sasaki Y; Yamada K; Yanagida E; Muto R; Kiryu M; Sone H; Seto M; Ohshima K; Takizawa J
Hematol Oncol; 2018 Feb; 36(1):166-173. PubMed ID: 29052238
[TBL] [Abstract][Full Text] [Related]
40. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
